Dbv Technologies(NASDAQ) DBVT

DBV Technologies makes skin patches to treat food allergies. These patches help children build tolerance to peanuts and milk. This method avoids putting allergens directly into the blood.

Treating Allergies Through the Skin

• Viaskin Peanut: Epicutaneous patch for children with peanut allergies; clinical trials for ages 4 to 11 are complete.
• Viaskin Milk: Immunotherapy for cow's milk protein allergy; currently in Phase I/II clinical trials.
• Viaskin Egg: Treatment for hen's egg allergy; currently in the pre-clinical development phase.
• MAG1C Test: Diagnostic tool for milk allergies in infants; developed in partnership with Nestlé Health Science.

Building the Foundation for Growth

• Aligned with the FDA in March 2025 on a regulatory pathway for the peanut patch.
• Raised $125.5 million through a private investment in April 2025.
• Generated $195.4 million in January 2026 from the full exercise of warrants following clinical results.
• Entered a letter of intent with Fareva in June 2026 for commercial-scale manufacturing.
• Signed a letter of intent with ICS in June 2026 to support potential U.S. distribution.

A Unique Immune Approach

DBV Technologies uses a proprietary method called epicutaneous immunotherapy to deliver medicine through a skin patch. This approach targets immune cells in the skin to activate the body without entering the bloodstream.

Tracking the Financial Data

• Cash and cash equivalents totaled $174.9 million on June 30, 2026.
• Net loss reached $50.4 million for the three months ended June 30, 2026, up 20% year over year.
• Operating expenses were $100.1 million for the six months ended June 30, 2026, up 43% year over year.
• Sales and marketing costs reached $10.4 million for the six months ended June 30, 2026, up 1426% year over year.
• Net cash used for operating activities was $101.7 million for the six months ended June 30, 2026.

The Evolution to Commercial Stage

DBV Technologies has transitioned from early research to preparing for large-scale product commercialization. The company is now focused on securing regulatory approvals and building its manufacturing and distribution infrastructure.